Lidocaine

English name lidocaine

also known as lidocaine hydrochloride · lignocaine · Xylocaine · lidocain · lidocaine HCl · Lidoderm · ZTlido · ALGRX 3268 · +93 more

Other / unclassified targets GOLT1A, TLR4 via inhibition

Developed for: neuropathy, painful · chronic pain syndrome · migraine disorder · interstitial cystitis · osteoarthritis, knee · colorectal cancer · headache disorder · myofascial pain syndrome
+212 more
· pulpitis · carpal tunnel syndrome · postherpetic neuralgia · female infertility · hemorrhoid · breast cancer · gastroesophageal reflux disease · pharyngitis · tinnitus · cancer · cataract · colon carcinoma · delirium · fibromyalgia · overactive bladder · pregnancy disorder · stroke disorder · trigeminal neuralgia · anxiety · arthropathy · cardiac rhythm disease · diabetic neuropathy · female reproductive system disorder · head and neck cancer · infertility disorder · intracranial hypotension · malignant pancreatic neoplasm · morbid obesity · obstetric disorder · pelvis syndrome · prostate cancer · rotator cuff syndrome · shoulder impingement syndrome · spinal cord injury · temporomandibular joint disorder · thyroid cancer · uterine inflammatory disease · vulvodynia · acquired aneurysmal subarachnoid hemorrhage · acute lung injury · adolescent idiopathic scoliosis · anterior cutaneous nerve entrapment syndrome · autism · bursitis · cerebrovascular disorder · cholelithiasis · cognitive disorder · colorectal neoplasm · constipation disorder · COVID-19 · cranial nerve palsy · dental pulp disorder · diabetes mellitus · diabetic polyneuropathy · disease of the tendon · endometriosis · frozen shoulder · herpes zoster · ileus · impacted teeth, multiple · intermediate coronary syndrome · leiomyoma · lumbar disk disease · musculoskeletal system disorder · obstructive sleep apnea syndrome · Parkinson disease · peripheral nerve lesion · premature ejaculation · pudendal neuralgia · radiculopathy · sickle cell disease · strabismus · subarachnoid hemorrhage · traumatic brain injury · traumatic encephalopathy · ulcer of lower limbs · ureterolithiasis · urinary tract obstruction · vertebral column disorder · abscess · acute opioid poisoning · acute respiratory distress syndrome · adult acute respiratory distress syndrome · allesthesia · atrial fibrillation · bacterial vaginosis · Barre-Lieou syndrome · bowel dysfunction · brain aneurysm · breast carcinoma · breast disorder · cerebral palsy · cervical cancer · chemotherapy-induced neuropathy · chemotherapy-induced oral mucositis · chronic pancreatitis · chronic ulcer of skin · cocaine dependence · common cold · complex regional pain syndrome · curariform drugs toxicity · dementia · digestive system disorder · dysmenorrhea · ecthyma · esophagitis · female breast carcinoma · glioblastoma · heart failure · hepatocellular carcinoma · hernia, double inguinal · hiatus hernia · hypertensive disorder · infectious neuropathy · inflammatory disease · insect Stings, hypersensitivity to · irritable bowel syndrome · ischemic disease · ischemic stroke · metastatic malignant neoplasm · migraine with aura · migraine without aura · Morton neuroma · mucositis · nephrolithiasis · non-small cell lung carcinoma · oropharynx squamous cell carcinoma · osteoarthritis, hand · otitis media · otorhinolaryngologic disease · pain agnosia · palmoplantar keratosis · pancreatitis · parkinsonian disorder · pelvic organ prolapse · periarthritis · periodontitis · plantar fasciitis · post-surgical hypoinsulinemia · pregnancy disorder with abortive outcome · proliferative diabetic retinopathy · pulmonary edema · radiation-induced neuropathy · restless legs syndrome · retinal detachment · sciatica · scorpion envenomation · sensory peripheral neuropathy · sleep disorder · small intestine disorder · spondylosis, cervical · stomatitis · syncope, familial vasovagal · systemic sclerosis · temporomandibular joint dysfunction syndrome · tendinitis · thalassemia · tonsillitis · tooth disorder · trichomonal vulvovaginitis · ulcerative stomatitis · urethral disorder · urinary bladder disorder · uterine disorder · ventricular fibrillation · ventricular tachycardia · vulvar disease · vulvovaginal candidiasis · acute stress disorder · anal fistula · ankylosing spondylitis · anxiety disorder · arthritic joint disease · cardiac arrest · cardiac valvular defect · clubfoot · complex regional pain syndrome type 1 · congenital deformities of limbs · coronary vasospasm · developmental dysplasia of the hip · epicondylitis · gallstones · hyperhidrosis palmaris ET plantaris · infectious discitis · intervertebral disk degenerative disorder · kidney cancer · large intestine disorder · laryngeal disorder · myopathy, congenital, with respiratory insufficiency and bone fractures · nasal disorder · neuroma · osteoarthritis, hip · pancreas disorder · peripheral neuropathy · persistent idiopathic facial pain · pilonidal sinus · piriformis syndrome · postoperative ventricular dysfunction · preeclampsia · pterygium · radiculitis · refractory malignant neoplasm · scoliosis · sexual disorder · spinal stenosis · subacute delirium · tendinosis · tenosynovitis · toe, misshapen · upper respiratory tract disorder · urinary system disorder · urolithiasis
Investigated by: Cairo University · Assiut University · Endo USA Inc., a Keenova Therapeutics Company · ZARS Pharma Inc. · Ain Shams University · Yonsei University
+680 more
· Tanta University · Scilex Pharmaceuticals, Inc. · Washington University School of Medicine · West China Hospital · Ankara City Hospital Bilkent · Copka Sonpashan · General Hospital of Ningxia Medical University · Muhammad · Aalborg University · Allergan · Aswan University Hospital · Duke University · Stanford University · The Catholic University of Korea · University of California, San Diego · Federal University of São Paulo · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Mayo Clinic · McMaster University · Medical University of Silesia · Oregon Health and Science University · Rigshospitalet, Denmark · The University of Texas Health Science Center, Houston · University of British Columbia · University of California, San Francisco · University of Campinas, Brazil · University of Sao Paulo · Anqing Municipal Hospital · Beijing Tiantan Hospital · Dr. Lutfi Kirdar Kartal Training and Research Hospital · Grünenthal GmbH · Johns Hopkins University · Mahidol University · Medical University of Warsaw · National Taiwan University Hospital · Northwestern University · Ohio State University · Rutgers, The State University of New Jersey · Taris Biomedical LLC · The Cleveland Clinic · University of Alabama at Birmingham · University of Saskatchewan · Aarhus University Hospital · Ahmadu Bello University Teaching Hospital · Ajou University School of Medicine · AlgoRx Pharmaceuticals · Assistance Publique - Hôpitaux de Paris · Ataturk University · Brigham and Women's Hospital · Dow University of Health Sciences · Hamilton Health Sciences Corporation · Hopital Foch · Hospices Civils de Lyon · Isifer AB · Jamia Millia Islamia · Kaohsiung Medical University Chung-Ho Memorial Hospital · Kasr El Aini Hospital · Khon Kaen University · Loma Linda University · Milton S. Hershey Medical Center · NYU Langone Health · Nantes University Hospital · National Cancer Institute (NCI) · Nordsjaellands Hospital · Northwell Health · Nuvo Research Inc. · Rennes University Hospital · Seoul National University Hospital · Shandong University · Silesian University of Medicine · Society of Family Planning · São Paulo Research Foundation · Universiti Kebangsaan Malaysia Medical Centre · University Health Network, Toronto · all 686 on the full record

Regulatory milestones approvals, filings & regulatory actions · 6 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansion	US (FDA)	ZTLIDO	—	2021-04-08	fda.gov ↗
Approved	EU (EMA)	Fortacin	—	2013-11-15	europa.eu ↗
Label expansion	US (FDA)	ZINGO	—	2009-01-08	fda.gov ↗
Label expansion	US (FDA)	XYLOCAINE	—	1981-02-23	fda.gov ↗
Label expansion	US (FDA)	LIDOPEN	—	1976-10-18	fda.gov ↗
Approved	US (FDA)	XYLOCAINE DENTAL	—	1948-11-19	fda.gov ↗

Trials 917 · started per year

today

US approved 1948

EU approved 2013

194719481949195019511952195319541955195619571958195919601961196219631964196519661967196819691970197119721973197419751976197719781979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 025 trials
Phase 0	NCT07707557	Dec 2025 → Jun 2026 overdue	—	Abbasi Shaheed Hospital	Active not recruiting	No outcome recorded
Phase 0	NCT06935552	Jun 2025 → Nov 2026 expected	—	Assiut University	Not yet recruiting	No outcome recorded
Phase 0	NCT06462573	Sep 2024 → Sep 2026 overdue	ureterolithiasis	Assiut University	Not yet recruiting	No outcome recorded
Phase 0	NCT06243120	Mar → Sep 2024	—	Ain Shams University	Unknown	No outcome recorded
Phase 0	NCT07169032	Jan → Feb 2024	—	Li Zhen Zhong	Completed	No outcome recorded
Phase 0	NCT05298761	Dec 2023 → Mar 2024	—	Sheikh Zayed Medical College	Unknown	No outcome recorded
Phase 0	NCT07709390	May 2023 → Jan 2029 expected	—	Ohio State University	Recruiting	No outcome recorded
Phase 0	NCT03095404	Oct 2022 → Aug 2025	—	McMaster University	Withdrawn	No outcome recorded Stop: Business
Phase 0	NCT05921292	Jul 2022 → Jan 2024	chronic ulcer of skin	Omeza, LLC	Completed	No outcome recorded
Phase 0	NCT06293807	Jun 2022 → Apr 2023	periodontal disorder	The University of Texas Health Science Center at San Antonio	Completed	No outcome recorded
Phase 0	NCT05060913	Nov 2021 → Mar 2022	—	Dow University of Health Sciences	Completed	No outcome recorded
Phase 0	NCT04192773	Apr 2021 → Dec 2027 expected	tinnitus	D. Bradley Welling, MD, PhD	Recruiting	No outcome recorded
Phase 0	NCT04648540	Dec 2020 → Aug 2022	—	Cairo University	Completed	No outcome recorded
Phase 0	NCT04583137	Nov 2020 → Nov 2022	—	Kfir Siag	Unknown	No outcome recorded
Phase 0	NCT04413799	Sep 2020 → Dec 2024	—	George Washington University	Terminated	No outcome recorded Stop: Enrollment
Phase 0	NCT04519463	Sep 2020 → Sep 2022	—	Muhamed Masalha	Unknown	No outcome recorded
Phase 0	NCT04774029	Jan → Apr 2020	vertebral disorder	Northwell Health	Completed	No outcome recorded
Phase 0	NCT03676725	Aug 2019 → Mar 2020	attention deficit-hyperactivity disorder, premenstrual tension	PhenoSolve, LLC	Completed	No outcome recorded
Phase 0	NCT04048278	Nov 2018 → Nov 2027 expected	malignant pancreatic neoplasm	University of Illinois at Chicago	Recruiting	No outcome recorded
Phase 0	NCT04732104	Jul 2018 → Jun 2020	—	Dow University of Health Sciences	Completed	No outcome recorded
Phase 0	NCT02955524	Mar 2018 → Jun 2020	—	University of Miami	Withdrawn	No outcome recorded
Phase 0	NCT04167189	Jan 2018 → Mar 2020	attention deficit-hyperactivity disorder	PhenoSolve, LLC	Completed	No outcome recorded
Phase 0	NCT03145207	Dec 2016 → Jan 2019	—	University of Maryland, Baltimore	Completed	No outcome recorded
Phase 0	NCT03323567	Jan 2016 → Oct 2017	temporomandibular joint disorder	Medical University of Silesia	Completed	No outcome recorded
Phase 0	NCT02088866	Mar 2014 → Aug 2015	tinnitus	University of California, Davis	Completed	No outcome recorded

Phase 148 trials · 3 met primary · 2 missed
Phase 1	NCT06747390	Apr 2025 → Nov 2026 expected	human papilloma virus infection, oropharynx squamous cell carcinoma	Ryan Carey	Recruiting	No outcome recorded
Phase 1	NCT06310200	Jan → May 2025 overdue	headache disorder	Wright State University	Active not recruiting	No outcome recorded
Phase 1	NCT06462781	Mar 2024 → May 2025	migraine disorder	The Cooper Health System	Completed	No outcome recorded
Phase 1	NCT06516861	Jan → Feb 2024	—	Arsil Radiansyah	Completed	No outcome recorded
Phase 1	NCT05501600	Nov 2022 → Nov 2023	—	Keith M Vogt	Completed	Mixed
Phase 1	NCT05417425	Sep 2022 → Oct 2023	ulcer of lower limbs	Omeza, LLC	Completed	No outcome recorded
Phase 1	NCT05343299	May 2022 → Jun 2023	—	Nîmes University Hospital	Completed	Missed primary
Phase 1	NCT05361369	May 2022	—	Exeltis Turkey	Completed	No outcome recorded
Phase 1	NCT04941040	Jul → Oct 2021	supratentorial cancer	Kasr El Aini Hospital	Completed	No outcome recorded
Phase 1	NCT04979923	Jul 2021	acute respiratory distress syndrome	Sheikh Zayed Medical College	Unknown	No outcome recorded
Phase 1	NCT05106400	Jul 2021	—	Scilex Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 1	NCT05912335	Jun 2021 → Feb 2022	tooth disorder	University of Campinas, Brazil	Completed	No outcome recorded
Phase 1	NCT04716699	Jan → Dec 2021	glioblastoma	University of California, Davis	Completed	No outcome recorded
Phase 1	NCT03177252	Oct 2020 → Sep 2021	brain neoplasm	Washington University School of Medicine	Withdrawn	No outcome recorded
Phase 1	NCT04784728	Aug 2019	—	Scilex Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 1	NCT03806595	Jul 2019 → Dec 2020	migraine disorder	University of British Columbia	Completed	No outcome recorded
Phase 1	NCT05589402	Jun 2019 → Jun 2026 overdue	spinal cord injury, stroke disorder	University of Texas Rio Grande Valley	Active not recruiting	No outcome recorded
Phase 1	NCT04185194	Jan 2019	—	Cairo University	Completed	No outcome recorded
Phase 1	NCT04162535	Nov 2018 → Dec 2023	colorectal cancer	Iuliu Hatieganu University of Medicine and Pharmacy	Unknown	No outcome recorded
Phase 1	NCT03797703	Nov 2018 → May 2020	hemorrhoid	Wake Forest University Health Sciences	Completed	No outcome recorded
Phase 1	NCT04319926	Sep 2018	—	Scilex Pharmaceuticals, Inc.	Completed	Met primary
Phase 1	NCT03310047	Oct 2017 → Mar 2018	—	Nordsjaellands Hospital	Completed	No outcome recorded
Phase 1	NCT04692896	Sep 2017 → Mar 2018	—	King Edward Medical University	Completed	No outcome recorded
Phase 1	NCT04320173	Feb → Mar 2017	—	Scilex Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 1	NCT04149938	Sep → Oct 2016	—	Scilex Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 1	NCT04150536	Jan 2016	—	Scilex Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 1	NCT04312750	Dec 2015	—	Scilex Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 1	NCT02593370	Oct → Nov 2015	bone disorder	Thomas F. Bendtsen	Completed	No outcome recorded
Phase 1	NCT02460627	May 2015 → Jan 2017	—	Northern Orthopaedic Division, Denmark	Unknown	No outcome recorded
Phase 1	NCT03265197	Mar → Oct 2015	tinnitus	saad elzayat	Completed	No outcome recorded
Phase 1	NCT02241096	Jan → Sep 2015	—	Children's Hospital Medical Center, Cincinnati	Terminated	No outcome recorded
Phase 1	NCT02679339	Jan → Aug 2015	herpes zoster	Centrexion Therapeutics	Terminated	No outcome recorded Stop: Enrollment
Phase 1	NCT04144192	Apr → Jul 2014	—	Scilex Pharmaceuticals, Inc.	Completed	Met primary
Phase 1	NCT02268968	Oct 2013 → Dec 2014	—	Mansoura University Children Hospital	Completed	No outcome recorded
Phase 1	NCT01879683	Jul 2013 → May 2014	interstitial cystitis	Allergan	Completed	No outcome recorded
Phase 1	NCT01541293	Sep 2012 → Oct 2013	—	University of North Carolina, Chapel Hill	Completed	Missed primary
Phase 1	NCT01463280	Jan 2011 → Dec 2013	venous thromboembolism	Klein, Jeffrey A., M.D.	Completed	No outcome recorded
Phase 1	NCT01150565	Jul 2010 → Sep 2011	interstitial cystitis	Allergan	Completed	No outcome recorded
Phase 1	NCT00964288	Jul → Nov 2009	neuropathy, painful	Biogen	Terminated	No outcome recorded
Phase 1	NCT01324843	Jun 2009 → May 2010	—	National Institute on Aging (NIA)	Completed	No outcome recorded
Phase 1	NCT00686231	May → Dec 2008	—	University of California, San Francisco	Completed	Met primary
Phase 1	NCT01425840	Mar → Nov 2008	—	University of Campinas, Brazil	Completed	No outcome recorded
Phase 1	NCT01054547	Sep → Dec 2006	—	University of Campinas, Brazil	Completed	No outcome recorded
Phase 1	NCT00566904	Sep 2006 → Aug 2008	postherpetic neuralgia	Biomedical Development Corporation	Completed	No outcome recorded
Phase 1	NCT00373893	Dec 2005 → Feb 2006	—	University of California, San Diego	Completed	No outcome recorded
Phase 1	NCT01355588	Aug → Sep 2005	—	Egalet Ltd	Completed	No outcome recorded
Phase 1	NCT00991848	Jan 2005 → Jul 2007	fibromyalgia	Federal University of São Paulo	Completed	No outcome recorded
Phase 1	NCT00308841	—	—	Suleyman Demirel University	Completed	Mixed

Phase 1/213 trials
Phase 1/2	NCT06875791	Dec 2025 → Dec 2026 expected	head and neck squamous cell carcinoma, mucositis	Fundacion Clinica Valle del Lili	Not yet recruiting	No outcome recorded
Phase 1/2	NCT05694858	Feb 2025 → Dec 2026 expected	cataract, glaucoma	Universiti Kebangsaan Malaysia Medical Centre	Recruiting	No outcome recorded
Phase 1/2	NCT06661902	Jan 2025 → Jan 2026	prostate cancer	University of Washington	Completed	No outcome recorded
Phase 1/2	NCT05573191	Oct → Nov 2022	—	General Hospital of Ningxia Medical University	Unknown	No outcome recorded
Phase 1/2	NCT05476679	Sep 2022 → Jun 2023	—	Raziel Therapeutics Ltd.	Completed	No outcome recorded
Phase 1/2	NCT04026945	Oct 2019 → Mar 2021	chronic pain syndrome	University of British Columbia	Completed	No outcome recorded
Phase 1/2	NCT03220113	Jul 2017 → Jul 2018	migraine with aura, migraine without aura	Corona Doctors Medical Clinics, Inc.	Unknown	No outcome recorded
Phase 1/2	NCT01654302	Sep 2013 → Sep 2014	osteoarthritis, knee	Thomas J. Schnitzer	Completed	No outcome recorded
Phase 1/2	NCT03117166	Jan → May 2010	—	Drexel University College of Medicine	Terminated	No outcome recorded
Phase 1/2	NCT00791024	Nov 2008 → Nov 2009	—	Ove Andersen	Completed	No outcome recorded
Phase 1/2	NCT01108562	Feb → Aug 2008	—	Loma Linda University	Withdrawn	No outcome recorded
Phase 1/2	NCT00977028	Jan 2005 → Jul 2011	—	Klein, Jeffrey A., M.D.	Unknown	No outcome recorded
Phase 1/2	NCT00540982	Feb 1997 → May 2010	lung cancer	City of Hope Medical Center	Completed	No outcome recorded

Phase 293 trials · 5 met primary · 7 missed
Phase 2	NCT07816159	Dec 2026 → Dec 2029 expected	subarachnoid hemorrhage	Rigshospitalet, Denmark	Not yet recruiting	No outcome recorded
Phase 2	NCT04414917	Nov 2026 → Nov 2029	neuropathy, painful	Rutgers, The State University of New Jersey	Suspended	No outcome recorded Stop: Business
Phase 2	NCT07361549	Sep 2026 → Dec 2030 expected	migraine disorder	Daniel A Tonetti, MD	Recruiting	No outcome recorded
Phase 2	NCT07094542	Sep 2026 → Nov 2029 expected	impacted teeth, multiple, myofascial pain syndrome	Rutgers, The State University of New Jersey	Not yet recruiting	No outcome recorded
Phase 2	NCT07700108	Jun 2026 → Jan 2029 expected	—	Ohio State University	Recruiting	No outcome recorded
Phase 2	NCT07054801	Jun 2026 → Jan 2027 expected	subarachnoid hemorrhage	Daniel Raper, MBBS	Recruiting	No outcome recorded
Phase 2	NCT07567274	May → Jul 2026 overdue	tinnitus	Leading Edge Clinic	Enrolling by invitation	No outcome recorded
Phase 2	NCT07268118	May 2026 → Jun 2027 expected	—	Beth Israel Deaconess Medical Center	Recruiting	No outcome recorded
Phase 2	NCT05729503	May 2026	anxiety	University of Calgary	Withdrawn	No outcome recorded
Phase 2	NCT07273916	Mar → May 2026 overdue	—	Hexsel Dermatology Clinic	Not yet recruiting	No outcome recorded
Phase 2	NCT07294118	Jan 2026 → Jun 2027 expected	acquired aneurysmal subarachnoid hemorrhage, headache disorder, opiate dependence	The University of Texas Medical Branch, Galveston	Recruiting	No outcome recorded
Phase 2	NCT07250867	Jan 2026 → Jan 2027 expected	—	Assiut University	Not yet recruiting	No outcome recorded
Phase 2	NCT07432399	Sep 2025 → May 2027 expected	colon carcinoma	Institute of Oncology Ljubljana	Recruiting	No outcome recorded
Phase 2	NCT07031206	Jul 2025 → May 2026 overdue	anxiety	The University of Texas Health Science Center, Houston	Not yet recruiting	No outcome recorded
Phase 2	NCT06955923	May → Aug 2025	myofascial pain syndrome	David Grant U.S. Air Force Medical Center	Completed	No outcome recorded
Phase 2	NCT07061847	Mar 2025 → Mar 2027 expected	migraine disorder	Northwell Health	Recruiting	No outcome recorded
Phase 2	NCT06433713	Dec 2023 → Mar 2024	—	Cairo University	Completed	No outcome recorded
Phase 2	NCT06109389	Oct 2023 → May 2024	migraine disorder	Alexandria University	Unknown	No outcome recorded
Phase 2	NCT05890703	Jun → Oct 2023	ecthyma, ulcer of lower limbs	Juerg Hafner	Unknown	No outcome recorded
Phase 2	NCT05737121	May 2023 → Jun 2026 overdue	interstitial cystitis	Vaneltix Pharma, Inc.	Recruiting	No outcome recorded
Phase 2	NCT05783219	May 2023 → Apr 2024	overactive bladder	University of Louisville	Completed	Met primary
Phase 2	NCT06862570	Dec 2022 → May 2023	pulpitis	28 Military Dental Centre Lahore	Completed	No outcome recorded
Phase 2	NCT05223075	Nov 2022 → Feb 2023	—	Fayoum University	Unknown	No outcome recorded
Phase 2	NCT05335070	Sep 2022 → Nov 2026 expected	—	Rutgers, The State University of New Jersey	Recruiting	No outcome recorded
Phase 2	NCT06532162	Jun 2022 → Aug 2024	—	Mount Sinai Hospital, Canada	Completed	No outcome recorded
Phase 2	NCT05365880	Mar 2022 → Mar 2025	headache disorder, ischemic stroke	University of Utah	Withdrawn	No outcome recorded Stop: Enrollment
Phase 2	NCT05017246	Jan 2022 → Jul 2024	uterine corpus leiomyoma	Washington University School of Medicine	Terminated	Met primary Stop: Enrollment
Phase 2	NCT05777122	Jan 2022 → Mar 2023	—	Sadaf Bashir	Unknown	No outcome recorded
Phase 2	NCT05193227	Oct 2021 → Apr 2026 overdue	—	University of British Columbia	Recruiting	No outcome recorded
Phase 2	NCT05078463	Sep 2021 → Aug 2022	thalassemia	Universiti Kebangsaan Malaysia Medical Centre	Completed	No outcome recorded
Phase 2	NCT04650282	Mar → Apr 2021	headache disorder, traumatic encephalopathy	University of Michigan	Terminated	No outcome recorded
Phase 2	NCT05906615	Jan 2021 → Jul 2023	chronic pancreatitis, malignant pancreatic neoplasm	Academic Medical Center - University of Amsterdam	Completed	No outcome recorded
Phase 2	NCT04250805	Oct 2020 → Jan 2024	cancer, eating disorder	University Hospital of Saint-Etienne	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT04467424	Jun → Nov 2020	—	University Hospital of Split	Completed	No outcome recorded
Phase 2	NCT05492669	Feb 2020 → Jul 2024	chronic pain syndrome	West China Hospital	Unknown	No outcome recorded
Phase 2	NCT03865940	Nov 2019 → Oct 2023	trigeminal neuralgia	Vanderbilt University Medical Center	Completed	Missed primary
Phase 2	NCT03430531	May 2019 → Jan 2020	intracranial hypotension	Milton S. Hershey Medical Center	Terminated	No outcome recorded
Phase 2	NCT03865147	Jan → Jul 2019	—	Medical Ethics UK Ltd	Unknown	No outcome recorded
Phase 2	NCT03578783	Dec 2018 → May 2021	premature ejaculation	Plethora Solutions Ltd	Completed	No outcome recorded
Phase 2	NCT03778008	Dec 2018 → Dec 2019	stomatitis	Second Affiliated Hospital of Nanchang University	Unknown	No outcome recorded
Phase 2	NCT03343080	Jul → Oct 2018	heart disorder	Mayo Clinic	Completed	No outcome recorded
Phase 2	NCT03560349	Jul 2018 → Jan 2019	intracranial hypotension	University of Utah	Withdrawn	No outcome recorded
Phase 2	NCT03825016	Aug 2017 → Jan 2020	—	Ain Shams University	Completed	No outcome recorded
Phase 2	NCT03197558	Jun → Sep 2017	eustachian tube disorder, otitis media with effusion	Tusker Medical	Completed	No outcome recorded
Phase 2	NCT03386552	Jun 2017 → May 2018	infertility disorder	Isifer AB	Unknown	Met primary
Phase 2	NCT03096444	May → Jul 2017	—	Gil Yosipovitch	Terminated	No outcome recorded
Phase 2	NCT03054844	Apr → Oct 2017	—	Columbia University	Completed	No outcome recorded
Phase 2	NCT03047057	Mar 2017 → Jul 2018	ileus	Assiut University	Completed	No outcome recorded
Phase 2	NCT02696720	May 2016 → Jun 2017	—	Brugmann University Hospital	Withdrawn	No outcome recorded Stop: Enrollment
Phase 2	NCT02763592	May 2016 → Mar 2017	neuropathy, painful	University Hospital, Clermont-Ferrand	Completed	No outcome recorded
Phase 2	NCT02591199	Sep 2015 → May 2018	interstitial cystitis	Urigen	Terminated	No outcome recorded Stop: Business
Phase 2	NCT02411110	May 2015 → Oct 2016	interstitial cystitis	Allergan	Completed	Missed primary
Phase 2	NCT02689856	May → Sep 2015	hemorrhoid	Citius Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 2	NCT02395042	Apr 2015 → Jun 2017	interstitial cystitis, ulcer disease	Allergan	Completed	Missed primary
Phase 2	NCT02577393	Apr 2015 → Jun 2022	esophagitis, lung neoplasm	Shandong Cancer Hospital and Institute	Unknown	No outcome recorded
Phase 2	NCT01929343	Jan 2014 → Mar 2016	cocaine dependence	Bryon Adinoff	Completed	No outcome recorded
Phase 2	NCT02033356	Jan → Feb 2014	—	Rigshospitalet, Denmark	Completed	No outcome recorded
Phase 2	NCT01824303	Mar 2013 → Nov 2014	interstitial cystitis	Allergan	Terminated	No outcome recorded
Phase 2	NCT01744197	Jan → Feb 2013	—	US Oncology Research	Completed	No outcome recorded
Phase 2	NCT01048177	Dec 2012 → Jun 2014	vulvodynia	Scripps Health	Withdrawn	No outcome recorded
Phase 2	NCT01544283	Mar 2012 → Jan 2014	shoulder impingement syndrome	Injury Care Medical Center	Unknown	No outcome recorded
Phase 2	NCT01690767	Dec 2011 → Dec 2014	urinary tract infection	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	Completed	Missed primary
Phase 2	NCT01552096	Dec 2011 → Oct 2013	inflammatory disease	Imam Abdulrahman Bin Faisal University	Completed	No outcome recorded
Phase 2	NCT01475253	Nov 2011 → Dec 2012	interstitial cystitis	Allergan	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT01405768	Jul 2011 → Oct 2012	dysplasia of cervix	Washington University School of Medicine	Completed	Missed primary
Phase 2	NCT01360749	May → Nov 2011	—	ISDIN	Completed	No outcome recorded
Phase 2	NCT01202487	Apr 2011 → Jan 2012	—	Children's Hospital of Eastern Ontario	Completed	No outcome recorded
Phase 2	NCT01314300	Mar 2011 → Jul 2014	neuropathy, painful, sickle cell disease	Centre Leon Berard	Completed	No outcome recorded
Phase 2	NCT01111773	Jun 2010 → Mar 2011	disease of the tendon	ZARS Pharma Inc.	Completed	No outcome recorded
Phase 2	NCT01106989	Jun → Dec 2010	myofascial pain syndrome	ZARS Pharma Inc.	Completed	No outcome recorded
Phase 2	NCT01115062	Apr 2010 → Jun 2011	—	Carol Morreale	Completed	No outcome recorded
Phase 2	NCT01055444	Mar → Aug 2010	shoulder impingement syndrome	ZARS Pharma Inc.	Completed	No outcome recorded
Phase 2	NCT01204242	Aug 2009 → Nov 2018	breast cancer	University of Virginia	Completed	No outcome recorded
Phase 2	NCT01155440	Jun 2009 → Oct 2011	colon carcinoma, diverticulitis, inflammatory bowel disease	McGill University Health Centre/Research Institute of the McGill University Health Centre	Completed	No outcome recorded
Phase 2	NCT00732589	Aug → Dec 2008	arthropathy, stroke disorder	Chulalongkorn University	Completed	No outcome recorded
Phase 2	NCT00609323	Jan → Jul 2008	postherpetic neuralgia	ZARS Pharma Inc.	Completed	No outcome recorded
Phase 2	NCT00590590	Oct 2007 → Jun 2009	vulvodynia	Lumara Health, Inc.	Completed	No outcome recorded
Phase 2	NCT00508976	Jun 2007 → Apr 2008	morbid obesity	Pinnacle Health System	Completed	No outcome recorded
Phase 2	NCT01329796	Mar 2007 → Jun 2009	dysmenorrhea, endometriosis	Isifer AB	Completed	Missed primary
Phase 2	NCT00589979	Mar 2007 → Jun 2008	osteoarthritis, knee	Endo USA Inc., a Keenova Therapeutics Company	Completed	Missed primary
Phase 2	NCT00811187	Mar 2007 → Mar 2008	—	Montefiore Medical Center	Completed	No outcome recorded
Phase 2	NCT00450242	Dec 2006 → Jan 2009	vulvodynia	University of North Carolina, Chapel Hill	Terminated	No outcome recorded Stop: Business
Phase 2	NCT00321347	May 2006 → May 2009	neoplasm	San Diego Hospice & Palliative Care	Withdrawn	No outcome recorded Stop: Enrollment
Phase 2	NCT00317070	Apr 2006 → Feb 2009	interstitial cystitis	Nova Scotia Health Authority	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT00256542	Jan → Sep 2006	interstitial cystitis, pelvis syndrome	Urigen	Completed	No outcome recorded
Phase 2	NCT00258622	Nov 2005 → Feb 2007	—	Danish Pain Research Center	Completed	No outcome recorded
Phase 2	NCT00904462	Aug 2004 → Sep 2005	osteoarthritis, knee	Endo USA Inc., a Keenova Therapeutics Company	Completed	No outcome recorded
Phase 2	NCT00904111	Aug 2004 → Oct 2005	chronic pain syndrome	Endo USA Inc., a Keenova Therapeutics Company	Completed	No outcome recorded
Phase 2	NCT00132405	May → Sep 2004	—	AlgoRx Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00108446	Oct 2003 → Mar 2006	irritable bowel syndrome	US Department of Veterans Affairs	Completed	No outcome recorded
Phase 2	NCT00449449	Sep 2003 → Sep 2006	infertility disorder	Isifer AB	Completed	Met primary
Phase 2	NCT02218203	Apr 2003 → Jan 2008	allesthesia, neuropathy, painful, spinal cord injury	Brigham and Women's Hospital	Completed	Met primary
Phase 2	NCT00372658	Jul 2002 → Oct 2004	infertility disorder	59th Medical Wing	Completed	No outcome recorded

Phase 2/324 trials · 3 met primary · 1 missed
Phase 2/3	NCT07445191	Mar → Jun 2026 overdue	temporomandibular joint disorder	Cairo University	Not yet recruiting	No outcome recorded
Phase 2/3	NCT07315490	Aug 2025 → Jan 2026 overdue	—	PAEC General Hospital, Islamabad	Active not recruiting	No outcome recorded
Phase 2/3	NCT07343128	Jun → Dec 2025	fibromyalgia	Sanliurfa Education and Research Hospital	Completed	No outcome recorded
Phase 2/3	NCT06740903	Aug 2024 → Aug 2025 overdue	cholecystitis	Sahiwal medical college sahiwal	Recruiting	No outcome recorded
Phase 2/3	NCT03226626	Dec 2021 → Jan 2022	infectious disease with sepsis, thrombotic disease	HK Surgical, Inc.	Unknown	No outcome recorded
Phase 2/3	NCT05153785	Nov 2021 → Jun 2025	liver cancer, substance-related disorder	Lund University Hospital	Completed	No outcome recorded
Phase 2/3	NCT04648891	Aug 2021 → Jul 2023	spasmodic dystonia	Mayo Clinic	Completed	No outcome recorded
Phase 2/3	NCT04741880	Jun 2021 → Dec 2022	cancer	Brazilian National Cancer Institute	Unknown	No outcome recorded
Phase 2/3	NCT04901065	May → Jun 2021	COVID-19	Evelyne D.Trottier	Completed	No outcome recorded
Phase 2/3	NCT03967197	Aug 2019 → Aug 2020	—	University of Montreal Hospital Centre (CHUM)	Completed	No outcome recorded
Phase 2/3	NCT02801786	Nov 2018 → Nov 2020	—	Federal University of Goiás	Unknown	No outcome recorded
Phase 2/3	NCT03725995	Jun 2017 → Jan 2018	—	Latakia University	Completed	Met primary
Phase 2/3	NCT03109392	May 2017 → Jun 2018	—	Post Graduate Institute of Medical Education and Research, Chandigarh	Completed	Met primary
Phase 2/3	NCT03199417	May 2017 → May 2018	osteoarthritis, knee	University of Michigan	Terminated	No outcome recorded Stop: Enrollment
Phase 2/3	NCT03531970	Aug 2016 → Aug 2017	—	Isfahan University of Medical Sciences	Completed	No outcome recorded
Phase 2/3	NCT02595463	Nov 2015 → Jun 2024	—	Ann & Robert H Lurie Children's Hospital of Chicago	Completed	Missed primary
Phase 2/3	NCT01955824	May → Nov 2014	interstitial lung disease, lung cancer, sarcoidosis, tuberculosis	Post Graduate Institute of Medical Education and Research, Chandigarh	Completed	No outcome recorded
Phase 2/3	NCT01961739	Oct 2013 → Mar 2014	hemorrhoid	University Hospital Dubrava	Unknown	No outcome recorded
Phase 2/3	NCT01384877	Dec 2011 → Dec 2017	—	British Columbia Cancer Agency	Completed	No outcome recorded
Phase 2/3	NCT02969733	Jan 2011 → Sep 2017	neuropathy, painful	University Hospital, Lille	Completed	No outcome recorded
Phase 2/3	NCT01155167	Jul 2010 → Aug 2011	—	University of California, San Francisco	Completed	Met primary
Phase 2/3	NCT01086150	Oct 2009 → Oct 2015	diabetic polyneuropathy	Albany Medical College	Completed	No outcome recorded
Phase 2/3	NCT00413127	Sep 2007 → Mar 2014	—	University Hospital Muenster	Terminated	No outcome recorded Stop: Enrollment
Phase 2/3	NCT00740285	Apr 2004 → Apr 2006	systemic sclerosis	Federal University of São Paulo	Completed	No outcome recorded

Phase 3118 trials · 9 met primary · 13 missed
Phase 3	NCT07869173	Jan 2027 → Jul 2029 expected	chronic pain syndrome	Nantes University Hospital	Not yet recruiting	No outcome recorded
Phase 3	NCT07795255	Nov 2026 → Sep 2030 expected	bladder transitional cell carcinoma	Florian Schroeck	Not yet recruiting	No outcome recorded
Phase 3	NCT07841080	Oct 2026 → Nov 2029 expected	ventricular fibrillation, ventricular tachycardia	Fondazione IRCCS Policlinico San Matteo di Pavia	Not yet recruiting	No outcome recorded
Phase 3	NCT07274254	Jul 2026 → Aug 2028 expected	sickle cell disease	Nantes University Hospital	Recruiting	No outcome recorded
Phase 3	NCT07661758	Jul → Nov 2026 expected	headache disorder	Tanta University	Recruiting	No outcome recorded
Phase 3	NCT07076641	Jul 2026 → Jul 2027 expected	digestive system disorder	Ramsay Santé	Not yet recruiting	No outcome recorded
Phase 3	NCT07414706	Mar 2026 → Jun 2028 expected	local anesthetic poisoning	Centre Hospitalier Universitaire, Amiens	Not yet recruiting	No outcome recorded
Phase 3	NCT07330726	Jan → Apr 2026 overdue	impacted teeth, multiple	Fayoum University	Not yet recruiting	No outcome recorded
Phase 3	NCT07299630	Dec 2025 → May 2026	—	Ain Shams University	Completed	No outcome recorded
Phase 3	NCT07212192	Nov → Dec 2025 overdue	pregnancy disorder	Phenikaa University	Not yet recruiting	No outcome recorded
Show all 118 trials opens the full record — a long page
Phase 4240 trials · 10 met primary · 15 missed
Phase 4	NCT07566312	Jan → Apr 2027 expected	—	Duke University	Not yet recruiting	No outcome recorded
Phase 4	NCT07497737	Dec 2026 → Apr 2027 expected	frozen shoulder	University Hospitals Cleveland Medical Center	Not yet recruiting	No outcome recorded
Phase 4	NCT07800468	Dec 2026 → Mar 2027 expected	diabetic polyneuropathy, type 2 diabetes mellitus	Wah Medical college , POF hospital	Not yet recruiting	No outcome recorded
Phase 4	NCT07857356	Oct → Nov 2026 expected	—	Pamukkale University	Recruiting	No outcome recorded
Phase 4	NCT07795593	Oct 2026 → May 2031 expected	diabetic kidney disease, diabetic neuropathy	University of Michigan	Not yet recruiting	No outcome recorded
Phase 4	NCT07429292	Sep → Dec 2026 expected	—	Duke University	Not yet recruiting	No outcome recorded
Phase 4	NCT07590830	Aug 2026 → Sep 2028 expected	—	Rennes University Hospital	Not yet recruiting	No outcome recorded
Phase 4	NCT07691359	Jul 2026 → Oct 2027 expected	neuropathy, painful, osteoporosis	University Hospital, Clermont-Ferrand	Not yet recruiting	No outcome recorded
Phase 4	NCT07552766	Jun 2026 → Dec 2028 expected	—	Nemours Children's Clinic	Recruiting	No outcome recorded
Phase 4	NCT07354217	Jun 2026 → Dec 2030 expected	paroxysmal atrial fibrillation	National Taiwan University Hospital	Not yet recruiting	No outcome recorded
Show all 240 trials opens the full record — a long page
Phase not applicable356 trials · 16 met primary · 17 missed
—	NCT07823244	Oct 2026 → Sep 2029 expected	—	Mahidol University	Not yet recruiting	No outcome recorded
—	NCT07612839	Sep → Dec 2026 expected	—	Hakan Emirkadı	Not yet recruiting	No outcome recorded
—	NCT07806162	Sep → Oct 2026 expected	—	Sohag University	Not yet recruiting	No outcome recorded
—	NCT07627100	Jun 2026 → Jun 2027 expected	—	Mayo Hospital Lahore	Not yet recruiting	No outcome recorded
—	NCT07657260	Jun → Jul 2026 overdue	—	Xidian University	Recruiting	No outcome recorded
—	NCT07607691	Jun → Oct 2026 expected	bursitis, chronic pain syndrome, frozen shoulder, rotator cuff syndrome	Ankara City Hospital Bilkent	Not yet recruiting	No outcome recorded
—	NCT07675616	May → Dec 2026 expected	lacrimal duct obstruction	Cairo University	Recruiting	No outcome recorded
—	NCT07203274	May → Dec 2026 expected	—	Aalborg University	Not yet recruiting	No outcome recorded
—	NCT07488832	Apr 2026 → Jan 2027 expected	—	Ankara City Hospital Bilkent	Recruiting	No outcome recorded
—	NCT07864155	Apr 2026 → Jan 2027 expected	—	Malatya Egitim Ve Arastirma Hastanesi	Recruiting	No outcome recorded
Show all 356 trials opens the full record — a long page
Comparator or background therapy1,091 trials
Phase 0	NCT06999057 Comparator	Aug 2026 → Aug 2027 expected	—	University of Central Florida	Recruiting	No outcome recorded
Phase 0	NCT07211399 Background	Jul 2026 → Dec 2030	substance-related disorder	Jacques E. Chelly	Withdrawn	No outcome recorded Stop: Business
Phase 0	NCT07675304 Comparator	May → Dec 2026 expected	—	National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland	Recruiting	No outcome recorded
Phase 0	NCT07511400 Comparator	Apr → Jun 2026	—	Medical University of Vienna	Completed	No outcome recorded
Phase 0	NCT07825155 Background	Mar → Jun 2026 overdue	carpal tunnel syndrome	Tanta University	Recruiting	No outcome recorded
Show all 1,091 trials opens the full record — a long page

Press releases naming this drug 47 releases

Date	Issuer	Release
2026-05-19	Sustained Therapeutics Inc.	Sustained Therapeutics Presents Positive Phase 2 Data for ST-01 in Podium Presentation at the American Urological Association 2026 Annual Meeting sustainedtherapeutics.com ↗
2026-05-06	Cutia Therapeutics（Wuxi）Co.,Ltd	VOLUNTARY ANNOUNCEMENT - CU-30101 (LOCALIZED TOPICAL LIDOCAINE AND TETRACAINE CREAM) OBTAINED DRUG MARKETING AUTHORIZATION BY THE NMPA cutiatx.com ↗
2025-06-26	Cutia Therapeutics（Wuxi）Co.,Ltd	VOLUNTARY ANNOUNCEMENT - RESULTS OF PHASE III CLINICAL TRIAL OF CU-30101 (LOCALIZED TOPICAL LIDOCAINE AND TETRACAINE CREAM) IN CHINA ACCEPTED FOR E-POSTER PRESENTATION AT THE 30TH ANNUAL MEETING OF CSD cutiatx.com ↗
2025-01-13	Scilex Pharmaceuticals, Inc.	Scilex Holding Company Announces Pain Medicine News Published Retrospective Claims Data on ZTlido® vs. Lidocaine 5% Patch gcs-web.com ↗
2024-11-28	Cutia Therapeutics（Wuxi）Co.,Ltd	VOLUNTARY ANNOUNCEMENT - RESULTS OF PHASE III CLINICAL TRIAL OF CU-40102 (TOPICAL FINASTERIDE SPRAY) AND CU-30101 (LOCALIZED TOPICAL LIDOCAINE AND TETRACAINE CREAM) IN CHINA WERE PRESENTED AT THE 19TH CDA ANNUAL MEETING cutiatx.com ↗
2024-10-30	Scilex Pharmaceuticals, Inc.	Scilex Pharmaceuticals Inc, a Wholly Owned Subsidiary of Scilex Holding Company, Announces Successful End of Phase II Meeting with FDA Leading to an Agreed Path Forward to NDA Upon Completion of Phase III Trials for Blockbuster Product Candidate, SP-103 (Lidocaine Topical System) 5.4%, a Next-Generation, Triple-Strength Formulation of ZTlido, for the Treatment of Chronic Neck Pain Associated with Muscle Spasms gcs-web.com ↗
2024-08-30	Scilex Pharmaceuticals, Inc.	Scilex Holding Company to Present Oral, Poster Presentations and Symposia on ZTlido (lidocaine topical system) at the 2024 Annual PAINWeek Conference in Las Vegas, NV on September 3-5, 2024 gcs-web.com ↗
2024-08-09	Scilex Pharmaceuticals, Inc.	Scilex Holding Company Enters into Master Distributor Agreement Among CH Trading Group and Devart Middle East for the Distribution of ZTlido® in Morocco, Tunisia, Libya, Jordan, Iraq, and South Africa gcs-web.com ↗
2024-07-30	Cutia Therapeutics（Wuxi）Co.,Ltd	VOLUNTARY ANNOUNCEMENT - DRUG MARKETING AUTHORIZATION APPLICATION FOR CU-30101 (LOCALIZED TOPICAL LIDOCAINE AND TETRACAINE CREAM) ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION cutiatx.com ↗
2024-07-17	Scilex Pharmaceuticals, Inc.	Scilex Holding Company Announces Collaboration to Leverage ACEA Therapeutics’ R&D Expertise and Local Market Connections to Support the Expansion of ZTlido® Program in ex-US and Potentially Provide Additional Access to Patients in Certain Key Markets in Far East Region gcs-web.com ↗
2024-04-16	Scilex Pharmaceuticals, Inc.	Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross and Net Sales for ZTlido® for the First Quarter 2024; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other Administrative Expenses gcs-web.com ↗
2024-04-09	Scilex Pharmaceuticals, Inc.	Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido® and ELYXYB® for Commercially Insured Patients and the addition of ELYXYB® to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing Pool gcs-web.com ↗
2024-03-15	Scilex Pharmaceuticals, Inc.	Scilex Holding Announces Issuance of Halal Certification for its ZTlido® product by Circle H International, Inc. gcs-web.com ↗
2024-02-26	Scilex Pharmaceuticals, Inc.	Scilex Holding Company Announces that ZTlido® Achieves a Major Milestone - Over One Million Patients Treated Since its Launch - and Two Additional Milestones Met gcs-web.com ↗
2024-02-20	Scilex Pharmaceuticals, Inc.	Scilex Holding Company Announces Publication in Anesthesiology Journal of Results from an Investigator-Initiated Research Study Using ZTlido® for the Treatment of Chronic Neck Pain¹ gcs-web.com ↗
2024-01-30	Cutia Therapeutics（Wuxi）Co.,Ltd	VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF CU-30101 (LOCALIZED TOPICAL LIDOCAINE AND TETRACAINE CREAM) IN CHINA REACHED PRIMARY ENDPOINT cutiatx.com ↗
2023-12-20	Scilex Pharmaceuticals, Inc.	Scilex Holding Company Announces that According to Prescription Data from Symphony Health, ZTlido® is the Most Prescribed Non-Opioid Branded Pain Treatment By Pain Specialists gcs-web.com ↗
2023-12-06	Scilex Pharmaceuticals, Inc.	Scilex Holding Company announces that ZTlido® (lidocaine topical system) will be added as a preferred agent to the Medicaid Preferred Drug List (PDL) in two new states: one Midwestern and one Southern State gcs-web.com ↗
2023-12-04	Scilex Pharmaceuticals, Inc.	Scilex Holding Company announces the addition of ZTlido® (lidocaine topical system) as a preferred agent to the Medicaid Preferred Drug List (PDL) of the State of Tennessee gcs-web.com ↗
2023-11-30	Scilex Pharmaceuticals, Inc.	Scilex Holding Company announces successful FDA audit of enhanced ZTlido® manufacturing facility in Japan gcs-web.com ↗
2023-11-17	Scilex Pharmaceuticals, Inc.	Scilex Holding Company Announces Issuance of a Second New Patent in the U.S. for Its Lead Commercial Product ZTlido® (lidocaine topical system) for a Method of Relieving Pain Through the Application of a Non-Aqueous Lidocaine-Containing Patch gcs-web.com ↗
2023-11-15	Scilex Pharmaceuticals, Inc.	Scilex Holding Company Announces Issuance of New Patent in the U.S. for Its Lead Commercial Product ZTlido® (lidocaine topical system) for a Method of Relieving Pain Through the Application of a Lidocaine-Containing Patch gcs-web.com ↗
2023-11-02	Scilex Pharmaceuticals, Inc.	Scilex Holding Company Announces New Data From Deeper Skin Penetration Studies to Support SP-103 (lidocaine topical system) 5.4%, a Triple Strength Formulation of ZTlido®, in Treatment of Musculoskeletal Pain Disorders gcs-web.com ↗
2023-09-14	Scilex Pharmaceuticals, Inc.	Scilex Holding Company Announces the Completion of its SP-103 (lidocaine topical system) 5.4%, Triple Strength Formulation of ZTlido®, Phase 2 trial which achieved its objectives to Evaluate the Safety and Efficacy of SP-103 in Subjects with Moderate to Severe Acute Lower Back Pain (LBP) gcs-web.com ↗
2023-09-12	Scilex Pharmaceuticals, Inc.	Scilex Holding Company Presented Oral and Poster Presentations on ZTlido (lidocaine topical system) at the 2023 Annual PAINWeek Conference Held in Las Vegas, NV gcs-web.com ↗
2023-08-23	Cutia Therapeutics（Wuxi）Co.,Ltd	VOLUNTARY ANNOUNCEMENT - ALL ENROLLED PATIENTS COMPLETED PHASE III CLINICAL TRIAL OF CU-30101 (LOCALIZED TOPICAL LIDOCAINE AND TETRACAINE CREAM) cutiatx.com ↗
2023-07-13	Scilex Pharmaceuticals, Inc.	Scilex Holding Company Announces Results From Independent Market Research Study Conducted with Pain Specialists and HCPs Treating Post-Herpetic Neuralgia (PHN) Pain on ZTlido® gcs-web.com ↗
2023-07-05	Sustained Therapeutics Inc.	A successful phase 1 study of an injectable lidocaine paste for spermatic cord block in men with chronic scrotal content pain sustainedtherapeutics.com ↗
2023-05-31	Scilex Pharmaceuticals, Inc.	Scilex Holding Company Enters Master Distributor Agreement Among CH Trading Group LLC (“CHT” or “Territories Distributor”) and Farouk, Maamoun Tamer & Co. (“Master Distributor”) For the Distribution of ZTlido® in the Kingdom of Saudi Arabia gcs-web.com ↗
2023-05-04	Scilex Pharmaceuticals, Inc.	Scilex Holding Company Announces Complete Enrollment of a Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 (lidocaine topical system) 5.4%, Triple Strength Formulation of ZTlido®, for the Treatment of Acute Low Back Pain gcs-web.com ↗
2023-04-21	Scilex Pharmaceuticals, Inc.	Scilex Holding Company Enters into Master Distributor Agreement with CH Trading Group LLC and AD Ports Group for the Distribution of ZTlido® in the Middle East and North Africa Region gcs-web.com ↗
2023-03-24	Scilex Pharmaceuticals, Inc.	Scilex Holding, A Subsidiary of Sorrento, Has Received From FDA a sNDA Approval for Ztlido® Label Expansion gcs-web.com ↗
2023-03-24	Scilex Pharmaceuticals, Inc.	Scilex Holding Company, a Subsidiary of Sorrento Therapeutics, Announces Continuous Sales Growth in ZTlido® and Expects to Complete Enrollment on its SP-102 (SEMDEXA™) Phase 3 Pivotal Trial Program in 2020 gcs-web.com ↗
2023-03-24	Scilex Pharmaceuticals, Inc.	Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary Announces Expansion of Ztlido® Managed Care Coverage for Additional 33 Million Lives gcs-web.com ↗
2023-03-24	Scilex Pharmaceuticals, Inc.	Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., announces continuous sales growth in ZTlido® with preliminary gross sales of approximately $8.1 million during the month of March 2022 and $18.4 million for 1Q2022 gcs-web.com ↗
2023-03-23	Scilex Pharmaceuticals, Inc.	Scilex Holding Company, a Sorrento Company, Announces Expanding Coverage to 30 Million Lives And Will Continue To Work To Access An Additional 20 Million Lives With One Of The Largest National Pharmacy Benefit Managers (PBMs) For ZTlido® (lidocaine topical system) 1.8% gcs-web.com ↗
2023-03-23	Scilex Pharmaceuticals, Inc.	Scilex Holding Company, a Sorrento Company, Announces Exclusive Product Distribution Agreement with CH Trading Group LLC to Expand Commercialization of ZTlido® across certain designated territories including Middle East and North Africa gcs-web.com ↗
2023-03-23	Scilex Pharmaceuticals, Inc.	Scilex Holding Company, a Sorrento Company, announces continued growth in ZTlido® in managed health care plans gcs-web.com ↗
2023-03-22	Scilex Pharmaceuticals, Inc.	Scilex Holding Company, a Sorrento Company, Announces That the FDA Has Granted Fast Track Designation for SP-103 (Lidocaine Topical System) 5.4%, Next Generation Triple Strength Formulation Of ZTlido®, For The Treatment Of Acute Low Back Pain (LBP) gcs-web.com ↗
2023-03-20	Scilex Pharmaceuticals, Inc.	Scilex Holding Company and CH Trading Group Announce Territory Distribution Agreement to Expand Commercialization of ZTlido® for the Middle East and North Africa (MENA) With $105 Million Minimum Multi-Year Purchase Commitment gcs-web.com ↗
2020-08-25	Impax Laboratories, LLC	Amneal Receives Abbreviated New Drug Application Approval for Lidocaine Patch, 5% amneal.com ↗
2020-04-22	Galderma R&D	Galderma receives approval for Restylane® Vital™, Restylane® Lyft™, and Restylane® Lidocaine in China galderma.com ↗
2016-02-01	Citius Pharmaceuticals, Inc.	Citius Pharmaceuticals Announces Results from Phase 2a Trial of Hydrocortisone and Lidocaine Combination Cream in Patients with Grade I and II Hemorrhoids citiuspharma.com ↗
2014-04-16	Noven Therapeutics	Noven Announces Settlement of Lidoderm® Patent Litigation noven.com ↗
2012-06-29	Noven Therapeutics	Noven Provides Update On Lidoderm® Patent Challenge noven.com ↗
2012-05-21	Noven Therapeutics	Noven Confirms Filing Of Abbreviated New Drug Application For Generic Lidocaine Patch 5% noven.com ↗
2011-10-20	Galderma R&D	Galderma announces positive US pivotal interim 6-month results for EMERVEL Classic Lidocaine compared to JUVEDERM Ultra galderma.com ↗

Evidence & citations 106 cited values

Every value below carries the sentence it was read from. 2,017 sources stand behind the page.

Field	Value	Cited text
Known as	lidocaine	“The drug: 5% lidocaine ointment, a local anesthetic, will be applied to the end of a device: long channeled cotton tipped applicator inserted into both nares and placed over...” NCT03112720 ↗ 1827 “A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate the Efficacy, Tolerability and Safety of MRX-7EAT Etodolac-Lidocaine Topical Patch in...” NCT01506154 ↗ “Participants will be induced using lidocaine 1 mg/kg IV, an opioid such a fentanyl (1-2 mcg/kg) IV, followed by 0.6 mg/kg IV rocuronium, and IV propofol with dosage at the...” NCT06029049 ↗ “Subjects in Group 2 (corticosteroid control) will receive a single ultrasound-guided intratendinous injection approximately (may be limited by tendon/soft tissue limitations of...” NCT03072381 ↗ “all of the patients of the experimental Celestone group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of Celestone®...” NCT02930057 ↗ “Ultrasound-guided injection of lyophilized platelet (30ng)+1.0 mL 1.0% Lidocaine+1.0 mL (10.0 mg/mL) Triamcinolone acetonide into the hypoechoic area of common extensor tendon...” NCT05648032 ↗ “Participants will receive one ultrasound-guided injection with 1 ml Kenalog 40mg/ml and 1 ml Lidocaine 10mg/ml superficial to the insertion of the gluteus medius and minimus...” NCT06456099 ↗ “General anesthesia without intraoperative opioids using dexmedetomidine, ketamine, lidocaine, sevoflurane, non-opioid co-analgesics, procedure-specific regional analgesia, and...” NCT07665463 ↗ “ALGRX 3268 (previously known as PowderJect® Dermal Lidocaine) is a system for needle-free, pain-free epidermal injection of lidocaine powder that provides local anesthesia...” NCT00132405 ↗ “Intra-articular injection with 25% dextrose will be carried out with the following details: 5 mL of 40% dextrose, 2 mL of lidocaine, and 1 mL of aqua dest are inserted into the...” NCT04557943 ↗ “Bladder instillation mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), 0.5% bupivacaine (10 mL of 5 mg/mL) plus...” NCT03463915 ↗ Show 1,817 more sources
Known as	1% Lidocaine	“1% Lidocaine” NCT02822196 ↗
Known as	2-(diethylamino)-N-(2.6-dimethylphenyl) acetamide	“Lidocaine (or 2-(diethylamino)-N-(2.6-dimethylphenyl) acetamide) is the main prototype of amino-amide local anesthetics.” NCT06431165 ↗
Known as	4% liposomal lidocaine (Brand name = LMX4)	“4% liposomal lidocaine (Brand name = LMX4)” NCT00676364 ↗
Known as	5% lidocaine-medicated plaster	“5% lidocaine-medicated plaster (LMP), which can block the Na+ channels on Aδ and C fibres” PMID 34341037 ↗ Aug 2021
Known as	5LP	“comparing 5% lidocaine medicated plaster (5LP) and placebo whether neuropathic pain symptoms” NCT02763592 ↗
Known as	Akten	“The three topical anesthetics being studied are 1) 0.5% proparacaine hydrochloride (generic, Akorn, Inc), 2) 0.5% proparacaine hydrochloride (generic, Akorn, Inc) PLUS 4%...” NCT01027611 ↗
Known as	ALGRX 3268	“ALGRX 3268 (previously known as PowderJect® Dermal Lidocaine) is a system for needle-free, pain-free epidermal injection of lidocaine powder that provides local anesthesia...” NCT00132405 ↗ 3 “ALGRX 3268 (Previously known as PowderJect(R) Dermal Lidocaine) is used for local anesthesia within 3 minutes to provide painless needle or cathether insertion for blood drawing.” NCT00146185 ↗ NCT00140088 ↗ NCT00146185 ↗
Known as	Alkalinized lidocaine	“Alkalinized lidocaine in the endotracheal tube (ETT) cuff decreases the incidence of cough and throat pain on emergence after surgery lasting more than 2 hours.” PMID 29189279 ↗ Feb 2018
Known as	Anestol pomade(lidocaine)	“Anestol pomade(lidocaine)” NCT05125796 ↗
Known as	Aritmal	“1 mL of triamcinolone acetonide 40 mg (KENACORT-A IM/Intra-articular Retard 40 mg ampoule) and 1 mL of 2% lidocaine (Aritmal 2% ampoule) will be injected over the plantar fascia.” NCT07120204 ↗ 1 “a total of 4 mL of local anesthetic solution consisting of 2 mL of 0.5% bupivacaine and 2 mL of 2% lidocaine (Aritmal) will be injected on each side.” NCT07608861 ↗
Known as	AritmalR	“Retrobulbar block was performed with 5 ml of 2% lidocaine hydrochloride (AritmalR, Osel, Istanbul, Turkey) in Group L patients.” NCT03189329 ↗
Known as	Aspercreme	“Aspercreme (Lidocaine Patch 4%)” NCT05106400 ↗
Known as	Buffered Lidocaine	“1% Buffered Lidocaine for injection, 0.50 mL administered one time intradermally in peripheral forearm” NCT01759459 ↗ 2 “Buffered Lidocaine (1% Lidocaine + 8.4% Sodium Bicarbonate, in a 3:1 ratio)” NCT06661902 ↗ “Drug: Buffered Lidocaine” NCT06974019 ↗
Known as	CNTX-2022	“CNTX-2022 (lidocaine gel, 40%)” NCT02679339 ↗
Known as	DEBOCAINE	“This arm will receive lidocaine injection (Debocaine®, 2%, Sigma-Tec, Egypt) with a dose of 80-200 mg equivalent to 10 ml lidocaine (20 mg/ml) is injected at four and eight...” NCT03362905 ↗ 2 “The lidocaine group will be administered a 1,000 ml distention medium containing 5 ml lidocaine per 250 ml (DEBOCAINE (LIDOCAINE) 2% 1 VIAL 50 ML, Sigma-Tec pharmaceutical...” NCT03701984 ↗ “Local infiltration with Lidocaine HCL 1%'Debocaine'” NCT05850455 ↗
Known as	depocaine	“5 mL of 2% lidocaine anhydrous solution (Depocaine) will be injected slowly along the lines of the edges of the perineal tears after delivery, with frequent aspirations to...” NCT02883179 ↗
Known as	Drug: lidocaine hydrochloride	“Drug: lidocaine hydrochloride” NCT00693043 ↗
Known as	Esracaine	“Pad soaked with lidocaine gel (Esracaine) left on the introitus for 5 minutes” NCT03210038 ↗
Known as	Experimental Group 1 triamcinolone and lidocaine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03127137 ↗
Known as	Hospira brand 1% Lidocaine in 20 mL vial	“Hospira brand 1% Lidocaine in 20 mL vial” NCT01759459 ↗
Known as	IV lidocaine	“IV lidocaine” NCT01319682 ↗
Known as	IVL	“Intravenous lidocaine (IVL), an alternative to epidural analgesia (EA) for laparotomies, has demonstrated anti-inflammatory and anti-hyperalgesic effects.” PMID 41790838 ↗ Mar 2026 2 “Randomisation will be into group Control (C) and Lidocaine (IVL).” NCT03410836 ↗ “perioperative intravenous lidocaine (IVL)” NCT05541640 ↗
Known as	Jetokain	“Patient were received infiltrative anesthesia with Lidocaine (Jetokain, Adeka Ilaç, Samsun, Türkiye): Active ingredient: Each 1 ml contains 20 mg lidocaine hydrochloride (HCL)...” NCT07145879 ↗
Known as	Jetokain Simplex	“A total of 0.3 mL of Lidocaine Hydrochloride (20 mg/mL, Jetokain Simplex, ADEKA, Samsun, Türkiye) was injected into each trigger point.” NCT07676799 ↗
Known as	L5%P	“Lidocaine transdermal patch (L5%P) is a local anesthetic medication with analgesic effect.” NCT05866653 ↗
Known as	Lambdalina	“Lambdalina® (Lidocaine 4% cream)” NCT01360749 ↗
Known as	LG4	“topical anesthesia is provided by lidocaine gel 4% (LG4)” NCT01145326 ↗
Known as	LID	“Lidocaine (LID) loading dose (1 mg/kg) followed by a continuous infusion till 24 h PO as 1.5 mg/kg/h.” NCT06907277 ↗
Known as	Lido-Patch	“This study investigated the efficacy of the Lido-Patch (lidocaine 5% medicated plaster) in treatment of pain caused by PHN” NCT03745404 ↗
Known as	lidocain	“Intravenous lidocain during the perioperative period has many beneficial effects in open procedures, such as an earlier return of gastrointestinal tract function, less...” NCT04987372 ↗ 26 “At the start of session 2, one area of the middle forearms of the participant will be located (4x4cm). On the area, local anesthetic cream (2.5% lidocain/2.5 prilocaine) will...” NCT05195177 ↗ “Ultrasound guided injection in Kagers triangle underneath the thickest part of the achilles tendon with 1ml Lidocain 5 mg/ml and 1 ml methylprednisolone 40mg/ml.” NCT02580630 ↗ “A 21-gauge, 40 mm needle is connected to a 2.5 cm3 syringe filled with 1 ml Triamcinolonhexacetonid 20mg/ml + 1 ml Lidocain 10 mg7ml.” NCT03804008 ↗ “1 ml methylprednisolon corticosteroid (40 mg Depo-Medrol®) mixed with 4 ml Lidocain (10 mg/ml) without adrenalin.” NCT01945749 ↗ “The femoral nerve blockade with lidocain is combined to the tumescent anesthesia.” NCT03475641 ↗ “For lidocain injection, 1ml 1% lidocain will also be peppered on the same area.” NCT02700906 ↗ “High Volume Image-Guided Injection with a saline/lidocain solution” NCT02996409 ↗ “1 ml Lidocain 10 mg7ml (Xylocain, AstraZeneca)” NCT03535896 ↗ “Drug: Lidocain” NCT07084753 ↗ NCT06265675 ↗ Show 16 more sources
Known as	Lidocain hydrochloride	“Lidocain hydrochloride 2 % with epinephrine” NCT05101785 ↗
Known as	lidocaine (2% Persocaine-E; Daroupakhsh, Tehran, Iran)	“lidocaine (2% Persocaine-E; Daroupakhsh, Tehran, Iran)” NCT03531970 ↗
Known as	Lidocaine 1% Injectable Solution	“Drug: Lidocaine 1% Injectable Solution” NCT04645823 ↗ 2 “Drug: Lidocaine 1% Injectable Solution” NCT06974019 ↗ “Lidocaine 1% Injectable Solution” NCT04505280 ↗
Known as	Lidocaine Gel	“Drug: Lidocaine Gel” NCT01837628 ↗
Known as	Lidocaine HCI	“Lidocaine HCI (1.7mL) 2% concentration with epinephrine (1:100,000) is the control agent.” NCT04787731 ↗
Known as	lidocaine HCl	“5 milliliters (mL) injection of corticosteroid (1cc Kenalog, 4cc Xylocaine) Kenalog - 40 (triamcinolone acetonide injectable suspension, USP) Xylocaine - MPF (lidocaine HCl...” NCT06703970 ↗ 17 “will receive a total of 2 mg.kg-1 of 2% lidocaine HCl (Xylocaine, Astra-Zeneca,) in 3 mL of normal saline (1.5 ml around each tonsil), 5 minutes before surgical incision.” NCT01552096 ↗ “Marcaine® (bupivacaine HCl) 0,5% and Xylocaine® (Lidocaine HCL) 2% = 2:1 Given in Femoropopliteal block group (Group F)” NCT06702202 ↗ “Lidocaine HCl (200 mg) in alkalinized buffer, administered as a single dose via intravesical instillation” NCT05737121 ↗ “Lidocaine Hcl spray (Xylocaine 10% Oral ) will be utilized to the research group” NCT04246255 ↗ “6.5 ml of 2% lidocaine (Lidocaine HCL -Sunny Pharmaceutical)” NCT07205757 ↗ “30 mg Ketorolac Tromethamine with 5% Lidocaine HCl IN” NCT01355588 ↗ “Local infiltration with Lidocaine HCL 1%'Debocaine'” NCT05850455 ↗ “Xylocaine - MPF (lidocaine HCl Injection, USP)” NCT06793982 ↗ “20 mg Lidocaine HCl+0.0125 mg epinephrine/ml” NCT02007408 ↗ “Lidocaine HCl 2% (200mg/10ml) 10 ml.” NCT02129270 ↗ Show 7 more sources
Known as	Lidocaine HCl 1%, USP	“This new formulation ST-CP is injected into the spermatic cord of patients in a very comparable way that the currently available lidocaine solution (Lidocaine HCl 1% USP) is...” NCT04026945 ↗
Known as	Lidocaine HCl 2%	“Patients in the lidocaine group receive an intravenous injection of 1.5 mg/kg Lidocaine HCl 2% at induction of anesthesia and continuous infusion of 1.5 mg/kg/h (ideal body...” NCT05103215 ↗
Known as	lidocaine hydrochloride	“The three topical anesthetics being studied are 1) 0.5% proparacaine hydrochloride (generic, Akorn, Inc), 2) 0.5% proparacaine hydrochloride (generic, Akorn, Inc) PLUS 4%...” NCT01027611 ↗ 104 “The purpose of this study is to determine if the combination product (URG101) is safe and effective versus its individual components (Heparin Sodium and Lidocaine...” NCT02591199 ↗ “Single injection into the glenohumeral joint under ultrasound guidance. Consists of 40 mg methylprednisolone acetate combined with 4 ml of 1% lidocaine hydrochloride. Delivered...” NCT06916650 ↗ “The active substances in Fydrane are: tropicamide 0.04 mg (anticholinergic), phenylephrine hydrochloride 0.62 mg (alpha sympathomimetic) and Lidocaine hydrochloride 2 mg (amide...” NCT04396301 ↗ “20 ml of Lidocaine Hydrochloride and 10 ml of Sodium hydrogen carbonate will be pulled up and mixed in a syringe on site, and 30 ml mixed solution in total will afterwards be...” NCT05415865 ↗ “For the local anesthesic, the doctor uses in both arms of the study a 20 ml vial of lidocaine hydrochloride without adrenaline for injection dosed at 2%.” NCT05178849 ↗ “will receive ultrasound-guided intra-articular SIJ injection with 40 mg of methylprednisolone with a uniform dose of 2 mL of 2% lidocaine hydrochloride.” NCT05134181 ↗ “Lidocaine Hydrochloride (Xylocaine) injection with Epinephrine is the traditionally method used to maintain local anesthesia throughout the procedure.” NCT03595449 ↗ “1 ml of 2% lidocaine hydrochloride and 1 ml of %0.9 saline will be used for creating a solution of 2 ml of 1% lidocaine for nerve block.” NCT04491474 ↗ “2% Lidocaine Hydrochloride jelly (Akorn, Buffalo Grove, IL) or Surgilube (Fougera, Melville, NY) using computer generated blocks of 10.” NCT00883103 ↗ “A total of 0.3 mL of Lidocaine Hydrochloride (20 mg/mL, Jetokain Simplex, ADEKA, Samsun, Türkiye) was injected into each trigger point.” NCT07676799 ↗ Show 94 more sources
Known as	lidocaine hydrochloride (Xylocaine)	“lidocaine hydrochloride (Xylocaine)” NCT03072290 ↗ 2 “lidocaine hydrochloride (Xylocaine)” NCT04364425 ↗ “lidocaine hydrochloride (Xylocaine)” NCT02708693 ↗
Known as	Lidocaine Hydrochloride ampule	“Lidocaine Hydrochloride ampule” NCT03921567 ↗
Known as	Lidocaine Hydrochloride Injection USP	“Control (Lidocaine Hydrochloride Injection USP Xylocaine® or Bupivacaine Hydrochloride Injection USP Marcaine®)” NCT05193227 ↗
Known as	Lidocaine hydrochloride topical solution, USP, 4%	“Lidocaine hydrochloride topical solution, USP, 4%” NCT05890495 ↗
Known as	Lidocaine Hydrochloride, Injectable	“Drug: Lidocaine Hydrochloride, Injectable” NCT04295330 ↗
Known as	Lidocaine hydrocholoride	“3. Lidocaine hydrocholoride buffered alone” NCT02591199 ↗
Known as	Lidocaine in Saline	“Drug: Lidocaine in Saline” NCT06792474 ↗
Known as	Lidocaine Injectable Solution	“Drug: Lidocaine Injectable Solution” NCT06872437 ↗
Known as	Lidocaine injection	“Drug: Lidocaine injection” NCT03140293 ↗
Known as	Lidocaine liposomal 4%	“Maxilene® (Lidocaine liposomal 4%)” NCT02616419 ↗
Known as	Lidocaine patch	“Lidocaine patch” NCT04238208 ↗
Known as	Lidocaine Patch 5%	“Commercially available Lidoderm® (lidocaine patch 5%)” NCT00903851 ↗ 1 “Lidocaine patch 5%” NCT00904397 ↗
Known as	Lidocaine Spray	“Lidocaine Spray was applied 60 seconds before to the area where the peripheral intravenous catheter application of the patients in the Experiment I Group (Lidocaine Spray) will...” NCT04859738 ↗
Known as	Lidocaine topical	“Drug: Lidocaine topical” NCT04732104 ↗
Known as	Lidocaine topical aerosol	“This arm will receive lidocaine spray (Lidocaine topical aerosol ®, 10%, Arab drug co., Egypt) with dose four puffs (50 ml, 10 mg/puff) will be applied to the cervical canal and cervix.” NCT03362905 ↗
Known as	Lidocaine topical system 1.8%	“Lidocaine topical system 1.8%” NCT04144192 ↗
Known as	Lidocaine Viscous	“Lidocaine Viscous” NCT06185933 ↗
Known as	lidocainhydrochlorid	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02456597 ↗
Known as	Lidocaïne Aguettant	“Lidocaïne Aguettant 20 mg/ml, injectable solution, applied to the skin with an impregnated compress, applied 15 minutes before infiltration performed by an experienced operator.” NCT05032508 ↗
Known as	Lidoderm	“Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain.” NCT00904020 ↗ 14 “Use of Topical Lidocaine (Lidoderm 5% Patch) to Reduce Pain in Patients With Diabetic Neuropathy: Does the Density and Subtype of Sodium Channels Affect Response?” NCT01086150 ↗ “Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 2 patches applied once daily (q24h) directly to the most painful area of the low back” NCT00904397 ↗ “Lidocaine 5% patch (Lidoderm®,Endo Pharmaceuticals Inc.), 2 patches applied directly to the most painful area of the low back once daily (q24h)” NCT00904111 ↗ “Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied topically to each affected knee every 24 hours (q24h)” NCT00904605 ↗ “Lidoderm (lidocaine patch 5%), up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain” NCT00904202 ↗ “a 5% Lidocaine (Lidoderm®) patch applied to the alternate forearm for the alternate time period.” NCT01688518 ↗ “5% lidocaine patch (Lidoderm®, Endo Pharmaceuticals Inc, Malvern, USA) 10 x 14 cm” NCT04238208 ↗ “three lidocaine patches 5% (Lidoderm® , Endo Pharmaceuticals, Chadds Ford, PA).” NCT04506034 ↗ “Commercially available Lidoderm (lidocaine patch 5%) was provided to patients” NCT00904540 ↗ “Patients will receive Lidoderm topical 5% lidocaine patches.” NCT03120351 ↗ Show 4 more sources
Known as	LidotopⓇ	“pretreatment with a 5% lidocaine patch (LidotopⓇ) (Group A)” NCT05732181 ↗
Known as	lignocaine	“mixture of intra-articular injection of 5.6 ml 25% dextrose and 1.4 ml 2% lignocaine to achieve a final concentration 20% dextrose with 0.4% lignocaine in the involved knee joint.” NCT07102225 ↗ 66 “Lignocaine is a local anaesthetic agent, which is also commonly used as a perioperative analgesic adjunct to accelerate rehabilitation and enhance recovery after surgery.” PMID 28683817 ↗ Jul 2017 “The aim of this study is to investigate the beneficial effects of intravenous lignocaine on reducing pain, nausea and vomiting after laparoscopic cholecystectomy.” NCT04182828 ↗ “lignocaine spray (LOX 10% spray, Neon laboratories LTD, Thane, India) will be used over vocal cords prior to intubation to blunt the sympathetic stimulation.” NCT03013075 ↗ “Lidocaine (Xylocaine), also called lignocaine, is a potent local anesthetic agent, widely used both topical and injection anesthesia.” NCT03265197 ↗ “Those randomised to the steroid group shall receive a single injection of 1 mL methylprednisolone \[40 mg\] and 1 mL 2% lignocaine.” NCT02304094 ↗ “5% lidocaine (lignocaine) medicated plaster or pregabalin as first-line therapy for relief of peripheral neuropathic pain.” PMID 19301937 ↗ 2009 “Dexamethasone 4mg (1ml) is a non-particulate corticosteroid and is used with the local anaesthetic lignocaine 1% (1ml).” NCT03240783 ↗ “A ring block with 0.5 mL plain lignocaine (2%) will be administered in the web spaces on either side of the digit” NCT06150794 ↗ “one under complete intravenous anesthesia (infusion of Propofol, Ketamine, Lignocaine and Dexmedetomidine)” NCT06390046 ↗ “Topical lignocaine is administered during bronchoscopy for local anaesthesia.” NCT02981277 ↗ Show 56 more sources
Known as	lignocaine HCl	“During nasal pack removal, the subjects will be randomly divided into 2 groups: the Lignocaine group (2% lignocaine HCl) and the Normal saline group (0.9% NaCl) using simple...” NCT03602287 ↗ 1 NCT02444260 ↗
Known as	lignocaine hydrochloride	“The conventional 2% lignocaine will be commercially available 2% lignocaine hydrochloride with 1:200,000 epinephrine, while the pre-warmed solution will be heated in a...” NCT06806202 ↗ 3 “Oral administration of a Strepsils® Max Plus lozenge containing the active ingredients amylmetacresol 0.6 mg, 2,4-dichlorobenzyl alcohol 1.2 mg, lignocaine hydrochloride 10mg...” NCT03944655 ↗ “The patients received pre-ovulatory pertubations with lignocaine hydrochloride 10 mg (n = 16) or ringer acetate (placebo, n = 9).” PMID 23921822 ↗ Sep 2013 “After achieving Local anesthesia using 2% lignocaine hydrochloride with 1:100,000 epinephrine” NCT02831374 ↗
Known as	lignospan	“Lidocaine (known as lignospan commercially)” NCT06450028 ↗
Known as	Liposomal Lidocaine	“Liposomal lidocaine 4% cream (Maxilene, RGR Pharma, Windsor, Ontario) is another anaesthetic cream” NCT00353002 ↗
Known as	LL30	“In the early 1940s, Nils Lofgren discovered lidocaine as a potent anesthetic, initially labelled LL30.” NCT03095404 ↗
Known as	LMP	“5% lidocaine-medicated plaster (LMP), which can block the Na+ channels on Aδ and C fibres” PMID 34341037 ↗ Aug 2021
Known as	LMX	“Lidocaine Topical Cream [LMX]” NCT03187392 ↗
Known as	LMX 4 (Lidocaine 4%)	“LMX 4 (Lidocaine 4%)” NCT01842373 ↗
Known as	LMX4	“Lidocaine 4% Topical Application Cream [LMX 4]” NCT03526874 ↗ 1 “LMX4 (Lidocaine 4%)” NCT01842373 ↗
Known as	LP5	“5% lidocaine plaster (LP5) is recommended for localized neuropathic pain” PMID 31009419 ↗ May 2019
Known as	Maxilene	“Liposomal lidocaine 4% cream (Maxilene, RGR Pharma, Windsor, Ontario) is another anaesthetic cream” NCT00353002 ↗ 1 “Maxilene® (Lidocaine liposomal 4%)” NCT02616419 ↗
Known as	Nebulized Xylocaine	“Nebulized Xylocaine” NCT04571879 ↗
Known as	PowderJect Dermal Lidocaine	“ALGRX 3268 (previously known as PowderJect® Dermal Lidocaine) is a system for needle-free, pain-free epidermal injection of lidocaine powder that provides local anesthesia...” NCT00132405 ↗
Known as	PowderJect(R) Dermal Lidocaine	“ALGRX 3268 (Previously known as PowderJect(R) Dermal Lidocaine) is used for local anesthesia to provide within 1-3 minutes painless needle or cathether insertion for blod drawing.” NCT00140088 ↗ 1 “ALGRX 3268 (Previously known as PowderJect(R) Dermal Lidocaine) is used for local anesthesia within 3 minutes to provide painless needle or cathether insertion for blood drawing.” NCT00146185 ↗
Known as	Pridocaine	“This arm will receive topical cream (Pridocaine ®, Global Napi, Egypt) with a dose of 2g lidocaine cream will be applied to the cervix via cotton swab.” NCT03362905 ↗
Known as	Promescent Lidocaine Spray	“Promescent Lidocaine Spray is a non-prescription drug that is marketed under an over-the-counter drug monograph (21 CFR Section 348.10 Subpart B (a)(2)) for male genital...” NCT02241460 ↗
Known as	Rapidocain(R)	“Lidocaine (Rapidocain(R)): 4ml of 1% Lidocaine” NCT01807962 ↗
Known as	Salonpas	“Salonpas (Lidocaine Patch 4%)” NCT05106400 ↗
Known as	ST-01	“The new formulation ST-01 is a sustained release lidocaine formulation” NCT05193227 ↗
Known as	Topicaine	“topical lidocaine gel (Topicaine)” NCT00382083 ↗
Known as	Topical Lidocaine	“Topical Lidocaine is applied to wrist prior to transradial cardiac catheterization in both study and control arms” NCT02832115 ↗
Known as	Vemcain Spray	“lidocaine spray (Vemcain® Spray)” NCT06885723 ↗
Known as	Versatis (Trade Mark)	“Versatis (Trade Mark)” NCT03765697 ↗
Known as	Viscous lidocaine	“Viscous lidocaine” NCT04515901 ↗
Known as	Xylocain	“1 ml Lidocain 10 mg7ml (Xylocain, AstraZeneca)” NCT03535896 ↗
Known as	xylocaina	“with an association of betamethasone dipropionate, betamethasone disodium phosphate {diprospan®}, plus lidocaine (xylocaina®).” NCT03196817 ↗
Known as	Xylocaine	“Participants will be randomized using computer generated allocation to receive 10% Xylocaine (lidocaine group) spray or normal saline 0.9% (placebo group), applied identically...” NCT02097017 ↗ 64 “In 2% lidocaine group infiltration (Xylocaine 2% Barrett Hodgson Pakistan Pvt limited), skin and subcutaneous tissue will be infiltrated with 3 ml of 2% lidocaine (dose of 60...” NCT04050059 ↗ “5 milliliters (mL) injection of corticosteroid (1cc Kenalog, 4cc Xylocaine) Kenalog - 40 (triamcinolone acetonide injectable suspension, USP) Xylocaine - MPF (lidocaine HCl...” NCT06703970 ↗ “Lidocaine (Xylocaine) has a better pharmacokinetic and pharmacodynamics profile than levobupivacaine and is also widely used as local anaesthetic agent in clinical practice.” NCT04397484 ↗ “will receive a total of 2 mg.kg-1 of 2% lidocaine HCl (Xylocaine, Astra-Zeneca,) in 3 mL of normal saline (1.5 ml around each tonsil), 5 minutes before surgical incision.” NCT01552096 ↗ “10mg of dexamethasone (1cc) mixed with 1cc of 2% preservative-free xylocaine (lidocaine) will be injected on each side of the stenotic segment under fluoroscopic guidance” NCT01995461 ↗ “Xray-controlled arthrodistension by injection of 1 ml of Triamcinolone Acetonide, combined with 10 ml of visipaque 270 contrast medium and 5 ml of Xylocaine.” NCT06176248 ↗ “Midazolam Plus Xylocaine - Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam.” NCT02314546 ↗ “Lidocaine Hydrochloride (Xylocaine) injection with Epinephrine is the traditionally method used to maintain local anesthesia throughout the procedure.” NCT03595449 ↗ “The steroid injection was using 1ml of 10 mg (10mg/ml) triamcinolone acetonide (Shincort) mixed with 1 ml of 2% lidocaine hydrochloride (Xylocaine).” NCT02708693 ↗ “The use of Lidocaine spray (Xylocaine 10%) is commonly available worldwide and is routinely used in our institution before fiberoptic laryngoscopy.” NCT04519463 ↗ Show 54 more sources
Known as	Xylocaine - MPF	“5 milliliters (mL) injection of corticosteroid (1cc Kenalog, 4cc Xylocaine) Kenalog - 40 (triamcinolone acetonide injectable suspension, USP) Xylocaine - MPF (lidocaine HCl...” NCT06703970 ↗ 1 “Xylocaine - MPF (lidocaine HCl Injection, USP)” NCT06793982 ↗
Known as	Xylocaine 1%	“1% lidocaine (Xylocaine 1%, Astra Zeneca, Egypt)” NCT02522130 ↗
Known as	Xylocaine 10% Oral	“Lidocaine Hcl spray (Xylocaine 10% Oral ) will be utilized to the research group” NCT04246255 ↗
Known as	Xylocaine 10% pump spray	“Lidocaine spray 10 % (Xylocaine 10% pump spray; AstraZeneca BV, Zoetermeer, The Netherlands)” NCT06354816 ↗
Known as	Xylocaine 2 %	“5 mL of 2 % viscous lidocaine solution (20 mg/mL) (Xylocaine 2 %, Astra Zeneca, London, UK)” NCT06185933 ↗
Known as	xylocaine AstraZeneca	“1% lidocaine hydrochloride (xylocaine AstraZeneca) 9 mL mixed with 1 mL of triamcinolone 40 milligrams (Kenacort Bristol Myers Squip)” NCT04143165 ↗
Known as	Xylocaine Jelly	“A syringe consists of six millimeters of two percent lidocaine gel (Xylocaine Jelly, AstraZeneca, Australia) for the active management group” NCT06864078 ↗
Known as	Xylocaine spray	“Xylocaine spray” NCT04901065 ↗
Known as	Xylocaine, Lidocaine Hydrochloride	“Xylocaine, Lidocaine Hydrochloride” NCT02595463 ↗
Known as	Xylocaine, lidocaine hydrochloride (HCl) Injection	“Xylocaine, lidocaine hydrochloride (HCl) Injection” NCT05378113 ↗
Known as	Xylocard	“Xylocaine (lidocaine) 2% and Xylocard (lidocaine) 10%” NCT05072314 ↗
Known as	ZTlido	“The objectives of this study are to evaluate the adhesion performance and pharmacokinetics of ZTlido (lidocaine topical system) 1.8% during swimming, showering, and under...” NCT04784728 ↗ 4 “ZTlido™ Lidocaine Topical System 1.8% (36 mg) Versus Lidoderm® Lidocaine Patch 5% (700 mg)” PMID 32606914 ↗ Jun 2020 “ZTlido 1.8% lidocaine patch application to both feet for 7 days up to 12 hours per day.” NCT06030297 ↗ “ZTlido (Lidocaine Topical System) 1.8%” NCT05106400 ↗ NCT04819581 ↗
Known as	Ztlido (lidocaine)	“Lignocaine, Xylocaine, Ztlido (lidocaine)” NCT05086224 ↗
Action	Inhibit	“Lidocaine is a class I (sodium channel block) antiarrhythmic drug.” NCT00587483 ↗
Modality	Other / unclassified	“local anesthetic” NCT00863889 ↗
Route	Topical	“S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)” NCT00107835 ↗
Target	TLR4	“by blocking Toll-like receptor 4/NF-κB signaling” NCT07000760 ↗